About us Contacts Drug interactions: 390 212
Drug search by name

Cardioquin and Mifeprex

Determining the interaction of Cardioquin and Mifeprex and the possibility of their joint administration.

Check result:
Cardioquin <> Mifeprex
Relevance: 21.01.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Talk to your doctor before using quiNIDine together with miFEPRIStone. Combining these medications may significantly increase the blood levels of quiNIDine, which may increase the risk and/or severity of side effects. Your doctor may be able to prescribe alternatives that do not interact, or you may need to briefly stop using quiNIDine while you are being treated with miFEPRIStone. In addition, because miFEPRIStone is cleared slowly from the body, the interaction may occur even after you have stopped taking it for a while. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

CONTRAINDICATED: Coadministration with mifepristone may significantly increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by mifepristone. When a single 80 mg dose of simvastatin, a sensitive CYP450 3A4 substrate, was administered following pretreatment with mifepristone 1200 mg once daily for 10 days, simvastatin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 7- and 10-fold, respectively. Likewise, the Cmax and AUC of simvastatin acid, the pharmacologically active metabolite, increased by approximately 18- and 16-fold, respectively.

MANAGEMENT: When mifepristone is used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, concomitant use of CYP450 3A4 substrates with narrow therapeutic ranges and high first-pass effect is considered contraindicated. These drugs include lovastatin, simvastatin, cyclosporine, ergot derivatives, fentanyl, oral midazolam, triazolam, pimozide, quinidine, sildenafil, sirolimus, and tacrolimus. The contraindication does not apply when mifepristone is used on a limited basis to terminate a pregnancy, but caution and close monitoring are advisable. Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).

References
  • "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.
  • "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.
  • He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7
Cardioquin

Generic Name: quinidine

Brand name: Quin-G, Cardioquin, Quinora, Quinidex Extentabs, Quinaglute Dura-Tabs, Quin-Release

Synonyms: n.a.

Mifeprex

Generic Name: mifepristone

Brand name: Mifeprex, Korlym

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction